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Introduction 
Recently, a novel antimicrobial agent kaikosin E
1
 (1, 
Figure 1a) was isolated from a culture supernatant of a 
lysobacter species by Sekimizu and co-workers, and was 
showed to be effective against Gram-positive bacteria 
including methicillin-resistant Staphylococcus aureus 
(MRSA).  Peptide 1 had potent antibiotic activity in 
mouse infection model with ED50 value of 0.6 mg/kg.  
Therefore, this compound is considered as a promising 
candidate for treatment of multidrug resistant bacterial 
infection.  
The structure of 1 is featured by a 37-membered 
macrocycle, five D-amino acid residues, N-methylation on 
peptide main chain, and C7 fatty acid moiety.  Peptide 1 
was suspected to target menaquinone-4 (Figure 1b), which 
is an essential component of the electron transport system 
on bacterial membranes, and to dissipate the membrane 
structure in S. aureus. In order to investigate further mechanism of action of 1, the total synthesis and 
structure-function relationship study were performed.  
 
Figure 1. (a) Structure of Kaikosin E (1). (b) Structure 
of menaquinone-4. 
Results and Discussion 
1. Total synthesis of kaikosin E and its enantiomer 
The solid-phase synthesis does not necessitate purification of synthetic intermediates, and thus is 
advantageous over the solution-phase counterpart, especially for rapid construction of 1.  Moreover, high 
dilution effect on the solid-phase was expected to facilitate the macrocyclization of the 37-membered ring of 1.  
Synthetic strategy to 1 is summarized in Scheme 1.  The side chain of allyl glutamate would be anchored to 
2-chloro-2-trityl resin (Barlos resin), and the following peptide elongation would give linear depsipeptide 3, 
which was to be cyclized to generate the peptide 2.  Then, all the side chain protecting groups (t-Bu, Tr, TBS 
and Boc) would be removed simultaneously with the cleavage of the peptide 2 from the Barlos resin to produce 
1.                  
The solid phase peptide synthesis (SPPS) started from allyl glutamate loaded resin 4 (Scheme 2).  The 
attachments of the six Fmoc amino acid residues and threonine fragment, which included the fatty acid moiety 
on its amine group, were realized by using the HBTU/HOBt activation method under the microwave irradiation, 
leading to 5.  Then, on-resin esterification of the secondary alcohol of 5 with Fmoc-L-Thr(t-Bu)OH was 
performed.  To compete the esterification reaction, the coupling with 10 equiv of Fmoc-L-Thr(t-Bu)OH, 
N,N’-diisopropylcarbodiimide, and DMAP were used for three cycles to generate 6.  After the subsequent Fmoc 
cleavage, a microwave-assisted protocol was re-applied for stepwise coupling of the three amino acid residues to 
furnish acyclic depsipeptide 3.  Deprotection of the allyl group of 3 with catalytic Pd(PPh3)4 and excess amount 
of morpholine followed by PyBOP-promoted macrolactamization, resulting in formation of resin bound lactam 2.  
Finally, cleavage of 2 from Barlos resin with 95% aqueous TFA completed within 1 hour at room temperature, 
and then the reaction mixture was stirred for additional 2 hours to remove all the protecting groups attached to 
the side chains.  After purification by the reversed-phase HPLC, kaikosin E (1) was obtained in 4.6% yield 
from the allyl glutamate loaded resin 4.  The NMR spectra and the retention time in the HPLC of synthetic 1 
agreed with those of natural 1.  A comparison of MIC values shows synthesized 1 is in good accordance with 
that of naturally isolated one. 
 
Scheme 1. Retrosynthesis of kaikosin E (1). 
  
Enantiomer of 1 (ent-1) was also prepared by the slightly modified conditions from the ones described 
above.  Interestingly, synthesized ent-1 exhibited similar MIC values with that of 1.  Retention of 
antimicrobial activity of ent-1 supported that 1 targets achiral menaquinone-4. 
 
 2. Synthesis and functional analysis of side chain-modified analogues 
Table 1. Minimal inhibitory concentration of 
synthetic kaikosin derivatives 
 
compound MIC 
(g/mL) 
compound MIC 
(g/mL) 
1  4 7 >128 
8 8 10 128 
9 4 11 64 
  12 >128 
 
Scheme 2. Total synthesis of kaikosin E (1). 
Scheme 3. Synthesis of side chain modified analogues. 
compound MIC (g/mL) 
1 (natural) 4 
1 (synthetic) 4 
ent-1 8 
 
One of the structural features of 1 is the C7 fatty acid attached to the threonine residue.  To evaluate the 
importance of the fatty acid moiety, alternative synthetic route was designed.  A series of side chain-modified 
kaikosin analogues would be prepared by the last-step acylation of common amine precursor 7 (Scheme 3).  
Kaikosin E amine precursor 7 was synthesized in 25.6 % yield by similar synthetic procedure for 1, and the 
acylation was successfully proceeded only at the amine group of the threonine residue.  Antimicrobial activity 
of the synthesized analogues were examined and summarized in Table 1.  These results suggested that 
particular length (n = 7) of side chain is important to exhibit antimicrobial activity (Table 1, 1, 8, 9 vs. 7, 10-12).  
For further investigation of the role of the C7 fatty acid of 1, the binding affinity of the synthetic analogues to 
menaquinone-4 are now being explored.  
 
Conclusion 
The first total synthesis of kaikosin E (1) and its analogues were achieved via macrocyclization on solid 
support.  To investigate the structure-function relationship of 1, alternative synthetic route via amine precursor 
7 was also established.  This work demonstrated that the solid phase approach was effective for rapid 
production of wide range of kaikosin E analogues.  MIC values of synthesized kaikosin E derivatives implied 
the importance of the C7 fatty acid moiety of 1 for its antimicrobial activity. 
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